GeneDx Holdings annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
GeneDx Holdings Stock-Based Compensation Growth & History (WGS)
GeneDx Holdings's stock-based compensation was $32.2M for fiscal 2025.
View full GeneDx Holdings company overviewGeneDx Holdings annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $32.2M | $23.0M | +251.96% |
| 2024 | 2024-12-31 | $9.1M | $9.5M | — |
| 2023 | 2023-12-31 | −$326,000 | −$42.3M | — |
| 2022 | 2022-12-31 | $42.0M | −$177.4M | −80.87% |
| 2021 | 2021-12-31 | $219.4M | $99.2M | +82.50% |
| 2020 | 2020-12-31 | $120.2M | $114.7M | +2093.20% |
| 2019 | 2019-12-31 | $5.5M | — | — |
GeneDx Holdings quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $6.3M | −$1.5M | −18.83% |
| Q1 2026 | 2026-03-31 | $9.0M | $5.0M | +125.86% |
| Q4 2025 | 2025-12-31 | $9.8M | $6.9M | +243.76% |
| Q3 2025 | 2025-09-30 | $10.6M | $7.0M | +191.14% |
| Q2 2025 | 2025-06-30 | $7.8M | $4.7M | +151.38% |
| Q1 2025 | 2025-03-31 | $4.0M | $4.4M | — |
| Q4 2024 | 2024-12-31 | $2.8M | — | — |
| Q3 2024 | 2024-09-30 | $3.6M | $3.2M | +745.58% |
| Q2 2024 | 2024-06-30 | $3.1M | $3.0M | +2777.78% |
| Q1 2024 | 2024-03-31 | −$451,000 | −$499,000 | — |
| Q3 2023 | 2023-09-30 | $430,000 | −$843,000 | −66.22% |
| Q2 2023 | 2023-06-30 | $108,000 | −$22.6M | −99.52% |
| Q1 2023 | 2023-03-31 | $48,000 | −$17.5M | −99.73% |
| Q4 2022 | 2022-12-31 | $422,000 | −$36.5M | −98.86% |
| Q3 2022 | 2022-09-30 | $1.3M | −$16.7M | −92.93% |
| Q2 2022 | 2022-06-30 | $22.7M | $23.2M | — |
| Q1 2022 | 2022-03-31 | $17.6M | −$147.4M | −89.36% |
| Q4 2021 | 2021-12-31 | $37.0M | — | — |
| Q3 2021 | 2021-09-30 | $18.0M | −$11.4M | −38.85% |
| Q2 2021 | 2021-06-30 | −$519,000 | — | — |
| Q1 2021 | 2021-03-31 | $165.0M | — | — |
| Q3 2020 | 2020-09-30 | $29.5M | — | — |
GeneDx Holdings stock-based compensation trends
Over the last five fiscal years, GeneDx Holdings's stock-based compensation decreased from $120.2M to $32.2M, a change of −$88.1M. The latest reported quarter, Q2 2026, shows $6.3M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review GeneDx Holdings source filings ↗